Mast Therapeuthicals MSTX - Buy

Molgradex Phase 2a ENCORE Studie wird gestoppt - Vertex Trikafta dominiert in CF

"The biotech will now squarely focus the development of Molgradex on its lead indication, autoimmune pulmonary alveolar proteinosis, which is in phase 3 (but hit a roadblock last year when it failed a primary endpoint) “and does not plan to conduct further development activities related to Molgradex in NTM.”

https://www.fiercebiotech.com/biotech/...l-cystic-fibrosis-drug-hopes

https://savarapharma.com/development/pipeline/

 

CEO & CBO verlassen das sinkende...

https://savarapharma.com/investors/press-releases/release/?id=12946

 

Zahlen für Q3/20

• Umsatz 0,3 Mio. $
  
• Verlust 11 Mio. $
  
• Cash 94 Mio. $
  
• MK 57 Mio. $
  
• Cash > MK
  

https://savarapharma.com/investors/press-releases/release/?id=12971

 

Phase3 AVAIL Studie verfehlt den primären Endpunkt

• weitere Entwicklung von AeroVanc wird gestoppt
  
• Reduzierung der Betriebskosten für die Anpassung an optimierte Entwicklungsprogramme
  
• Entwicklung des Apulmiq-Programms wird eingestellt
  
• Ressourcenkonzentration auf Molgradex in aPAP
  

https://savarapharma.com/investors/press-releases/release/?id=13001

 

113 Mio. $ Offering

• 45,8 Mio. neue Aktien zu 1,45$
  
• 32,2 Mio. "pre-funded warrants" zu je 1,449$
  

"Savara intends to use the net proceeds from this offering for working capital to support operations, including but not limited to clinical development, manufacturing, regulatory, and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly referred to as Molgradex) in autoimmune pulmonary alveolar proteinosis (aPAP) program and the IMPALA 2 trial, and general and administrative expenses."

https://savarapharma.com/investors/press-releases/release/?id=13106

 

https://seekingalpha.com/news/...touted-its-experimental-lung-therapy  

Einige Insider haben sich offenbar  an dem Offering beteiligt

https://www.gurufocus.com/stock/SVRA/insider?search=savara

 

ich bin heute aus Zufall auf diese Aktie aufmerksam geworden. Kann mit eventuell jemand kurz was zu dieser Firma schreiben? Dankeschön.  

aber rein charttechnisch, google doch selber mal  

https://savarapharma.com/investors/press-releases/release/?id=13401  

Zahlen für Q3/21

• keine Umsätze
  
• Verlust 10,5 Mio. $
  
• Cash 171 Mio. $
  
• MK 120 Mio. $
  

- Company Believes it is Sufficiently Capitalized Through 2025, ~18 Months Beyond Anticipated IMPALA-2 Top-Line Data Readout at End of Q2 2024

https://savarapharma.com/investors/press-releases/release/?id=13651

Interessantes Kursniveau, geringer Cashburn

 

https://www.ariva.de/news/...quarter-year-end-2023-financial-11171748